Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Reliance One-Step Multiplex Supermix, a highly sensitive and robust reagent mix for detection and quantification of up to five RNA or DNA targets in one reaction.
HERCULES, Calif —Bio-Rad Laboratories, Inc., NYSE: BIO and BIOb) today announced the launch of the Reliance One-Step Multiplex Supermix, a highly sensitive and robust reagent mix for detection and quantification of up to five RNA or DNA targets in one reaction.
One-step RT-qPCR–based applications are increasingly being used in life science research to quickly quantify genes of interest directly from many RNA samples simultaneously. The applications are used in particular and for virus/pathogen detection and for high-throughput screening. Reliance One-Step Multiplex Supermix offers robust, sensitive amplification and detection of up to five targets under a wide range of conditions, including challenging templates, difficult targets, or targets that are in the presence of PCR inhibitors. With its room temperature stability, the supermix can be easily integrated into automated workflows.
“The Reliance One-Step Multiplex Supermix was specifically formulated to offer increased sensitivity and rapid results to address a wide range of RNA detection questions,” said Yann Jouvenot, Bio-Rad Marketing Manager, Gene Expression. “Used as part of a workflow along with our CFX Automation System II and PrimePCR Probe Assays, the supermix helps researchers maximize their throughput as well as the quality of their RT-qPCR data,” he added.
About Reliance One-Step Multiplex Supermix
Reliance One-Step Multiplex Supermix is a ready-to-use, single-tube reagent mix optimized for sensitive amplification of up to five targets in a single reaction. It is formulated with an optimal enzyme blend including a new Reliance reverse transcriptase and Sso7d fusion polymerase and an advanced buffer to maximize sensitivity and efficiency in multiplex RT-qPCR reactions. Its extended assembled reaction stability (up to 24 hours) is adapted for high-throughput automated workflows. When used as part of a workflow with Bio-Rad’s CFX Automation System II and PrimePCR Probe Assays, the Reliance One-Step Multiplex Supermix enables researchers to maximize throughput and quality of RT-qPCR data, processing 40 plates or more in 24 hours.
For additional information and to learn how it can enhance your one-step RT-qPCR in a multiplexed setting and with automated workflows, please visit bio-rad.com/RelianceOneStep.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact:
Bio-Rad Laboratories, Inc.
Angela Ra
510-741-2669
angela_ra@bio-rad.com
